Drug intelligence / Profile preview

ATP124

Development stage: Preclinical
Lead developer: AMAL Therapeutics
Modality: Vaccines & Immunotherapeutics

Overview

ATP124 is a lead cancer vaccine developed by the Swiss biotech company Amal Therapeutics. It is designed for the treatment of colorectal cancer and leverages Amal's proprietary KISIMA technology platform for therapeutic tumor vaccination. The preclinical development of ATP124 is being advanced with funds secured from a CHF 3 million Series A financing round.

Targets

TLR2 (Toll-like Receptor 2)TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on ATP124.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP124.

Explore the full profile